Study of two drugs with or without chemo for HER2-positive stomach cancer
Part of Cancer, Digestive system clinical trials.
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive stomach cancer or cancer where the stomach meets the esophagus that has spread to nearby areas but not to distant organs.
- You are between 18 and 75 years old.
- You are able to be up and active (ECOG score 0 or 1).
- Your heart pumps well (LVEF of 50% or more) and you have no major heart problems.
- Your liver, kidney, and blood counts are within normal ranges (check with your doctor).
- You have not had prior treatment with certain immunotherapy drugs (PD-1, PD-L1, or CTLA-4 inhibitors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs (KN026 and possibly KN-046) with standard chemotherapy for people with HER2-positive colorectal cancer or bile duct cancer that has not been treated yet. The goal is to see if this combination is safe and effective.
This trial tests KN026 together with chemotherapy in people with HER2-positive advanced stomach (or gastro-esophageal junction) cancer that has already grown despite first-line treatment with trastuzumab plus chemotherapy. It may help by targeting HER2 while also using chemotherapy to control the cancer.
This trial tests a combination of three drugs (BC001, Sintilimab, and XELOX chemotherapy) for people with advanced or metastatic HER-2 negative stomach cancer or cancer where the stomach meets the esophagus. The goal is to see if this combination works better than standard treatments.
This trial tests a new combination of drugs (Disitamab Vedotin, Trastuzumab, and Tislelizumab) against standard chemotherapy plus Trastuzumab (with or without Pembrolizumab) for people with advanced or metastatic stomach or gastroesophageal junction cancer that has high levels of HER2. The goal is to see if the new combination works better.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This trial tests a combination of two targeted drugs (KN026 and another drug) as a first treatment for advanced HER2-positive stomach cancer. It may be an option if you have not had any prior therapy for your advanced cancer and are in good general health.
Hear when a new HER2-positive Locally Advanced Resectable Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.